BioCardia, Inc. (BCDA): Nasdaq/NYSE listing notice — BioCardia regains Nasdaq compliance after raising $7.35M through equity offerings

BioCardia, Inc.

Raised net proceeds of $0.7M (Apr), $0.5M (Jun), $5.1M (Sep public offer), and $1.0M from ATM sales (Apr–Sep 2025).
Believes stockholders' equity now exceeds the $2.5M minimum for continued listing under Nasdaq Rule 5550(b)(1).
Earlier Nasdaq extension to Sep 29, 2025; compliance will be monitored at next periodic report.
Warrants exercisable earlier of 2030 or PMDA approval of CardiAMP Cell Therapy System.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

BioCardia, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 1, 2025, BioCardia, Inc. (the “Company,” “we,” “us” and “our”) received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its amount of stockholders’ equity had fallen below the $2,500,000 required minimum for continued listing set forth in Nasdaq Listing Rule 5550(b)(1). As noted in the Original 8-K, the Company had until May 16, 2025 to provide Nasdaq with a specific plan to achieve and sustain compliance. The Company submitted its plan to regain compliance on May 15, 2025

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

BioCardia, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-25-029768

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.